AR118750A1 - UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK - Google Patents

UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK

Info

Publication number
AR118750A1
AR118750A1 ARP200101129A ARP200101129A AR118750A1 AR 118750 A1 AR118750 A1 AR 118750A1 AR P200101129 A ARP200101129 A AR P200101129A AR P200101129 A ARP200101129 A AR P200101129A AR 118750 A1 AR118750 A1 AR 118750A1
Authority
AR
Argentina
Prior art keywords
cyclopropylsulfonyl
azetidin
pyrimidin
acetonitrile
crystalline form
Prior art date
Application number
ARP200101129A
Other languages
English (en)
Inventor
Timothy Andrew Woods
Jingdan Hu
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of AR118750A1 publication Critical patent/AR118750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona un método para preparar una forma cristalina de 2-(3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-1-(ciclopropilsulfonil)azetidin-3-il)acetonitrilo y su utilización en el tratamiento de afecciones dermatológicas tales como dermatitis atópica y prurito. Reivindicación 1: Un proceso para preparar 2-(3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-1-(ciclopropilsulfonilo)azetidin-3-il)acetonitrilo cristalino sustancialmente polimórficamente puro caracterizado por el patrón de difracción de rayos X en polvo que comprende un pico a 5,34º, 10,68º, 14,26º, 16,06º, 16,39º, 16,48º, 18,26º, 18,65º, 21,05º, 21,76º, 22,68º, o 26,75º (± 0,2º 2q), cuyo proceso comprende la cristalización de un solvente seleccionado del grupo que consiste en un alcohol C₁₋₅, un alquiléter C₂₋₈, un acetato de alquilo C₂₋₈, un cianuro de alquilo C₂₋₅, una alquilcetona C₃₋₉ y un solvente aromático, o una mezcla de los mismos; en donde el solvente o la mezcla de solventes tienen una actividad de agua de menos de 0,7.
ARP200101129A 2019-04-24 2020-04-22 UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK AR118750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962837972P 2019-04-24 2019-04-24

Publications (1)

Publication Number Publication Date
AR118750A1 true AR118750A1 (es) 2021-10-27

Family

ID=70614675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101129A AR118750A1 (es) 2019-04-24 2020-04-22 UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK

Country Status (11)

Country Link
US (2) US11548895B2 (es)
EP (1) EP3958968A1 (es)
JP (2) JP7241916B2 (es)
KR (1) KR20210141634A (es)
CN (1) CN114466681A (es)
AR (1) AR118750A1 (es)
AU (2) AU2020262100B2 (es)
BR (1) BR112021020508A2 (es)
CA (1) CA3134750A1 (es)
MX (1) MX2021012849A (es)
WO (1) WO2020219524A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3958968A1 (en) 2019-04-24 2022-03-02 Elanco Us Inc. A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
KR20230092945A (ko) * 2020-10-23 2023-06-26 엘랑코 유에스 인코포레이티드 특정한 입자 크기 분포를 갖는 jak 억제제
EP4263559A1 (en) 2020-12-18 2023-10-25 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
AU2022331810A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Fusion proteins for treating atopic dermatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214483B (zh) 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
DK2288610T3 (en) 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2016141891A1 (zh) 2015-03-11 2016-09-15 苏州晶云药物科技有限公司 Jak抑制剂的晶型及其制备方法
AR104918A1 (es) 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
WO2019003249A1 (en) 2017-06-28 2019-01-03 Mylan Laboratories Limited POLYMORPHIC FORMS OF BARICITINIB
EP3958968A1 (en) 2019-04-24 2022-03-02 Elanco Us Inc. A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor

Also Published As

Publication number Publication date
JP2023071922A (ja) 2023-05-23
US20200339585A1 (en) 2020-10-29
AU2020262100B2 (en) 2023-03-16
CN114466681A (zh) 2022-05-10
AU2023203627A1 (en) 2023-07-06
EP3958968A1 (en) 2022-03-02
BR112021020508A2 (pt) 2021-12-07
JP7241916B2 (ja) 2023-03-17
KR20210141634A (ko) 2021-11-23
MX2021012849A (es) 2022-02-24
WO2020219524A1 (en) 2020-10-29
US11548895B2 (en) 2023-01-10
AU2020262100A1 (en) 2021-11-11
US20230056365A1 (en) 2023-02-23
JP2022530441A (ja) 2022-06-29
CA3134750A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AR118750A1 (es) UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
MX340124B (es) Anticuerpos biespecificos.
CA2922933C (en) 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors
NZ739645A (en) Form i of compound a, process for its preparation, and its use in the manufacture of a medicament for treating thyroid hormone resistance-associated diseases
EP4276095A3 (en) Processes for preparing ask1 inhibitors
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
RU2016144197A (ru) Фунгицидные производные n'-[2-метил-6[2-алкоксиэтокси]-3-пиридил]-n-алкилформамидина для применения в сельском хозяйстве
UA116644C2 (uk) Сполуки біариламіду як інгібітори кінази
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
NZ737725A (en) Crystalline forms of a bruton’s tyrosine kinase inhibitor
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
MX2014000359A (es) Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii.
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
MD4489C1 (ro) Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină
MX2019006207A (es) Forma polimorfica de sepiapterina.
WO2021250468A3 (en) Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5- methylphenyl)-v-[(ls)-2-cyclopropyl-l-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-v-prop-2-ynyl-l,3-thiazol-2-amine
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
MY167395A (en) Method for producing glufosinate p free acid
EP3600290A1 (en) Novel modulators of the sigma-2 receptor and their method of use
JP2022132444A (ja) ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer